ALK-Abelló

ALK is a Denmark-based, global specialty pharmaceutical company focused on allergy. For over a century, we have been at the forefront of long-term allergy treatment and innovation, working with passion and dedication to help people living with this chronic disease, their families and the healthcare professionals who treat them. We are present in 46 markets worldwide, with offices in more than 20 countries and production sites in the USA, Spain, France, and Denmark. Our global presence reflects our commitment to address allergy across the world. Currently, we reach 3.1 million patients annually worldwide. Our approximately 2,800 employees have entered the second century of ALK’s existence with a unified mission: to help five million people living with allergies by 2030 through continuous growth and innovation. Building on our deep understanding of the biological mechanisms behind allergies, we have developed a range of allergy immunotherapy treatments and management solutions that form the core of our current product portfolio. A key component of these products is natural allergens, such as grass pollen and house dust mites. At ALK, we grow, collect, and harvest tons of these natural raw materials annually at our production facilities and take them through rigorous analysis, standardisation, and quality controls. We call this unique process “From farm to pharma”. Learn more about our scientific expertise and focus areas here . Discover more about our unique production processes here . Find more information about the Board of Directors at ALK on our Investor site here . The Executive Leadership Team at ALK includes the following executives. You can find their photos for download under Press and learn more about each member of the team on our career site . These two members of the Executive Leadership Team are registered with the Danish Business Authority and legally constitute ALK’s Board of Management. The history of ALK is a history of ‘firsts’. Decades of pushing boundaries and raising standards have placed us at the forefront of our industry and for more than 100 years, we have consistently devised and developed major advances for the treatment of allergy. Ever since 1923, when pharmacist Peter Barfod and physician Kaj Baagøe documented the first pharmaceutically manufactured allergy preparation, ALK has led the way in allergy treatment, and our history includes demonstrating how to manufacture allergen extracts, establishing a standardised method for large-scale manufacturing, and introducing new, more convenient treatment formulations. On 9 June 1923, Doctor Kaj Baagøe and pharmacist Peter Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital. The production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergological Laboratory Copenhagen). ALK develops the technique to accurately identify the proteins that provoke allergies. Based on the technique to identify the allergy-triggering proteins accurately, ALK develops a standardised process for manufacturing allergen extracts. ALK has the world’s first sublingual allergy immunotherapy tablet approved in Europe. ALK changes its name to ALK, referring to Allergological Laboratory Copenhagen, and introduces a new logo. ALK-Abelló remains the legal name of the company. For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document. ALK’s digital patient engagement platform, klarify.me, is launched, offering a broad range of services to help people manage their allergies. ALK announces an entry into food allergy treatment and begins the development of a sublingual immunotherapy tablet for peanut allergies. On 9 June 2023, ALK celebrated its 100-year anniversary, marking that the company has been a pioneer in fighting allergies for 100 years –